Accéder au contenu
Merck

Principaux documents

Voir toute la documentation

Passer à

1202005

USP

Dihydroergotamine mesylate

United States Pharmacopeia (USP) Reference Standard

Synonyme(s) :

Dihydroergotamine methanesulfonate salt

Se connecter pour consulter les tarifs organisationnels et contractuels.

Sélectionner une taille de conditionnement

Changer de vue
ConditionnementRéférenceDisponibilitéPrix
500 mg
Vérifier la disponibilité des articles du panier
407,00 €

A propos de cet article

Formule empirique (notation de Hill) :
C33H37N5O5 · CH4O3S
Numéro CAS:
6190-39-2
Poids moléculaire :
679.78
NACRES:
NA.24
PubChem Substance ID:
329749596
UNSPSC Code:
41116107
MDL number:
MFCD00058615

407,00 €

Vérifier la disponibilité des articles du panier
​
Demander une commande groupée
Service technique
Besoin d'aide ? Notre équipe de scientifiques expérimentés est là pour vous.
Laissez-nous vous aider

grade

pharmaceutical primary standard

API family

dihydroergotamine

manufacturer/tradename

USP

application(s)

pharmaceutical (small molecule)

format

neat

storage temp.

2-8°C

SMILES string

CS(O)(=O)=O.[H][C@@]12Cc3c[nH]c4cccc(C1C[C@H](CN2C)C(=O)N[C@]5(C)O[C@]6(O)N([C@@H](Cc7ccccc7)C(=O)N8CCC[C@@]68[H])C5=O)c34

InChI

1S/C33H37N5O5.CH4O3S/c1-32(35-29(39)21-15-23-22-10-6-11-24-28(22)20(17-34-24)16-25(23)36(2)18-21)31(41)38-26(14-19-8-4-3-5-9-19)30(40)37-13-7-12-27(37)33(38,42)43-32;1-5(2,3)4/h3-6,8-11,17,21,23,25-27,34,42H,7,12-16,18H2,1-2H3,(H,35,39);1H3,(H,2,3,4)/t21-,23?,25-,26+,27+,32-,33+;/m1./s1

InChI key

ADYPXRFPBQGGAH-WVVAGBSPSA-N

Application

Dihydroergotamine mesylate USP reference standard, intended for use in specified quality tests and assays as specified in the USP compendia.

Biochem/physiol Actions

Agonist at vascular serotonin receptors; partial agonist at α-adrenergic and dopamine D2 receptors; vasoconstrictor.
Vascular serotonin receptor agonist; vasoconstrictor.

Analysis Note

These products are for test and assay use only. They are not meant for administration to humans or animals and cannot be used to diagnose, treat, or cure diseases of any kind.  ​

Other Notes

Sales restrictions may apply.

Comparer avec des articles similaires

Voir la comparaison complète

Montrer les différences

1 of 1

Cet article
Y0000831D19500001440003
Dihydroergotamine mesylate United States Pharmacopeia (USP) Reference Standard

USP

1202005

Dihydroergotamine mesylate

Dihydroergotamine for peak identification European Pharmacopoeia (EP) Reference Standard

Y0000831

Dihydroergotamine for peak identification

Dihydroergotamine mesilate European Pharmacopoeia (EP) Reference Standard

D1950000

Dihydroergotamine mesilate

Methysergide maleate United States Pharmacopeia (USP) Reference Standard

USP

1440003

Methysergide maleate

manufacturer/tradename

USP

manufacturer/tradename

EDQM

manufacturer/tradename

EDQM

manufacturer/tradename

USP

grade

pharmaceutical primary standard

grade

pharmaceutical primary standard

grade

pharmaceutical primary standard

grade

pharmaceutical primary standard

format

neat

format

neat

format

neat

format

neat

application(s)

pharmaceutical (small molecule)

application(s)

pharmaceutical (small molecule)

application(s)

pharmaceutical (small molecule)

application(s)

pharmaceutical (small molecule)

storage temp.

2-8°C

storage temp.

-

storage temp.

2-8°C

storage temp.

2-8°C

API family

dihydroergotamine

API family

dihydroergotamine

API family

dihydroergotamine

API family

methysergide

Still not finding the right product?

Explore all of our products under

pictograms

Exclamation mark
GHS07

signalword

Warning

Hazard Classifications

Acute Tox. 4 Dermal - Acute Tox. 4 Inhalation

Classe de stockage

11 - Combustible Solids

flash_point_f

Not applicable

flash_point_c

Not applicable

Faites votre choix parmi les versions les plus récentes :

Certificats d'analyse (COA)

Lot/Batch Number

It looks like we've run into a problem, but you can still download Certificates of Analysis from our Documents section.

Si vous avez besoin d'assistance, veuillez contacter Service Clients

Déjà en possession de ce produit ?

Retrouvez la documentation relative aux produits que vous avez récemment achetés dans la Bibliothèque de documents.

Consulter la Bibliothèque de documents

S B Shrewsbury et al.
British journal of pharmacology, 154(6), 1254-1265 (2008-05-27)
The effects of intrapulmonary artery (i.p.a.) administration of dihydroergotamine mesylate (DHE) were evaluated. Conscious beagle dogs (n=4) were given DHE via the i.p.a. or i.v. route as two 0.014 mg kg(-1) doses and a 0.14 mg kg(-1) dose given 60
Xiaoyan Chen et al.
Journal of chromatography. B, Analytical technologies in the biomedical and life sciences, 768(2), 267-275 (2002-03-13)
A sensitive and specific procedure for the simultaneous determination of dihydroergotamine (DHE) and its 8'-hydroxylated metabolite (8'-OH-DHE) in human plasma was developed and validated. The analytes were extracted from plasma samples by liquid-liquid extraction, separated through a Zorbax C18 column
Drugs in R&D, 4(6), 376-377 (2003-10-31)
MT 300 is an injectable formulation of dihydroergotamine mesylate (DHE; a serotonin 5-HT1 receptor agonist) that is being developed by POZEN for the acute treatment of migraine. POZEN intends to present MT 300 as a prefilled syringe that can be
Afficher tous les articles scientifiques apparentés

Numéro d'article de commerce international

RéférenceGTIN
1202005-250MG04061838712905

Questions

Évaluations

Aucune valeur de notation

Filtres actifs